Form 8-K - Current report:
SEC Accession No. 0001193125-25-283191
Filing Date
2025-11-14
Accepted
2025-11-14 16:41:09
Documents
20
Period of Report
2025-11-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d874883d8k.htm   iXBRL 8-K 35619
2 EX-1.1 d874883dex11.htm EX-1.1 231951
3 EX-4.1 d874883dex41.htm EX-4.1 61713
4 EX-5.1 d874883dex51.htm EX-5.1 14468
5 EX-99.1 d874883dex991.htm EX-99.1 10031
6 EX-99.2 d874883dex992.htm EX-99.2 6882
10 GRAPHIC g874883g1113154751195.jpg GRAPHIC 3621
11 GRAPHIC g874883g1113155053303.jpg GRAPHIC 2534
12 GRAPHIC g874883g1114131007495.jpg GRAPHIC 3498
  Complete submission text file 0001193125-25-283191.txt   591414

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA annx-20251112.xsd EX-101.SCH 2846
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE annx-20251112_lab.xml EX-101.LAB 18756
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE annx-20251112_pre.xml EX-101.PRE 11707
22 EXTRACTED XBRL INSTANCE DOCUMENT d874883d8k_htm.xml XML 3768
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650) 822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39402 | Film No.: 251487491
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)